阿奇霉素与罗氟司特在COPD患者中的比较有效性:模拟目标试验
该研究采用模拟目标试验设计,基于Optum Clinformatics数据库2011年3月至2024年8月数据,纳入7550对倾向评分匹配的40岁以上活动性COPD新用药患者,比较阿奇霉素与罗氟司特对中重度急性加重风险的影响。结果显示阿奇霉素组首次中重度急性加重风险较罗氟司特组降低17%(HR 0.83,95%CI 0.79-0.87),需治疗人数为15(95%CI 12-21)。
要点
- 阿奇霉素较罗氟司特降低COPD中重度急性加重风险17%。
- 需治疗15例患者可预防1例中重度急性加重。
- 结果在预设敏感性和亚组分析中稳健。
核心结论
- 在活动性COPD患者中,阿奇霉素使用与中重度急性加重可能性降低相关,相比罗氟司特。
研究设计与样本
- 模拟目标试验,数据来自Optum Clinformatics Data Mart数据库2011年3月1日至2024年8月31日。
- 纳入年龄>40岁、活动性COPD且连续参保至少183天、新开始口服维持阿奇霉素或罗氟司特的患者,排除其他肺部疾病或阿奇霉素替代适应症者。
- 采用倾向评分匹配,共纳入7550对匹配患者,平均年龄70岁,56%为女性。
主要发现
- 队列中阿奇霉素或罗氟司特组首次中重度COPD急性加重的未调整发生率为1.2每人年。
- 与罗氟司特相比,阿奇霉素与首次中重度COPD急性加重风险降低17%相关(HR 0.83,95%CI 0.79-0.87)。
- 需治疗人数为15(95%CI 12-21)。
- 结果在预设敏感性和亚组分析中稳健。
临床怎么用
- 对于活动性COPD患者,阿奇霉素可能较罗氟司特更有效降低中重度急性加重风险。
- 本研究未评估比较安全性,临床决策需结合安全性数据及即将发表的大型随机对照试验结果。
局限性
- 本研究未评估阿奇霉素与罗氟司特的比较安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the risk of moderate or severe exacerbations of chronic obstructive pulmonary disease (COPD) among new users of azithromycin versus roflumilast in a population of patients with active COPD treated in routine clinical practice. DESIGN: Target trial emulation. DATA SOURCE: Optum Clinformatics Data Mart Database from 1 March 2011 to 31 August 2024. PARTICIPANTS: Patients aged >40 years with active COPD and at least 183 days of continuous insurance enrolment who initiated a new oral prescription for maintenance azithromycin or roflumilast. Those with evidence of other pulmonary conditions or alternative indications for azithromycin were excluded. Propensity score matching was used between treatment groups. MAIN OUTCOME MEASURES: The primary outcome was time to first moderate or severe COPD exacerbation. Cox proportional hazards models estimated hazard ratios. RESULTS: A total of 7550 matched pairs of patients initiating azithromycin versus roflumilast were included in the cohort. The mean age of patients was 70 years, and 56% were women. The unadjusted incidence of a first moderate or severe COPD exacerbation among patients in the cohort receiving azithromycin or roflumilast was 1.2 per person year. Compared with roflumilast, azithromycin was associated with a 17% reduction in the hazard of first moderate or severe COPD exacerbation (hazard ratio 0.83, 95% confidence interval (CI) 0.79 to 0.87; number needed to treat 15, 95% CI 12 to 21). These results were robust across a range of prespecified sensitivity and subgroup analyses. CONCLUSIONS: Among patients with active COPD, azithromycin use was associated with a reduced likelihood of moderate or severe COPD exacerbations compared with roflumilast use. Although this study did not assess the comparative safety of these agents, it provides evidence on treatment outcomes that may complement forthcoming data from a large randomised controlled trial. STUDY REGISTRATION: Centre for Open Science Real-World Evidence Registry https://osf.io/95d2v.
引用
- Portela GT, Wang SV, Suissa S, et al. Comparative effectiveness of azithromycin versus roflumilast in patients with chronic obstructive pulmonary disease: emulated target trial. BMJ. 2026. PMID: 42556860. doi:10.1136/bmj-2026-100111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。